Global Biosimilar Monoclonal Antibodies Market Report 2025

Biosimilar Monoclonal Antibodies Global Market Report 2025 – By Type (Synthetic Chemicals, Biopharmaceuticals, Other Types), By Compound (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab), By Application (Chronic & Autoimmune Diseases, Oncology, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

Biosimilar Monoclonal Antibodies Global Market Report 2025

Report Price : $4490.00 $3592.00 | Pages : 250 | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Biosimilar Monoclonal Antibodies Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN

Biosimilar Monoclonal Antibodies Market Definition

Biosimilar monoclonal antibodies refer to a member of the family of biosimilars. Large, intricate proteins are typically given as part of the treatment for conditions like cancer or rheumatoid arthritis. They are employed by the immune system to recognize and destroy foreign substances, including bacteria, viruses, and others.

The main types of biosimilar monoclonal antibodies are synthetic chemicals, biopharmaceuticals, and others. Any pharmaceutical drug product made from, derived from, or semi-synthesized from biological sources is known as a ‘biopharmaceutical’, sometimes known as a ‘biologic medical product’, or ‘biologic’. The different compounds include infliximab, rituximab, abciximab, trastuzumab, adalimumab, and bevacizumab and are used in various applications such as chronic and autoimmune diseases, oncology, and others.

Biosimilar Monoclonal Antibodies Market Segmentation

The biosimilar monoclonal antibodies market covered in this report is segmented –

1) By Type: Synthetic Chemicals, Biopharmaceuticals, Other Types

2) By Compound: Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab

3) By Application: Chronic & Autoimmune Diseases, Oncology, Other Applications

Subsegments:

1) By Synthetic Chemicals: Small Molecule Drugs, Chemical Synthesis Products

2) By Biopharmaceuticals: Monoclonal Antibodies, recombinant proteins, Vaccines, Other Biopharmaceuticals

3) By Other Types: Antibody-Drug Conjugates, Fusion Proteins, Biosimilars Of Other Biologics

Biosimilar Monoclonal Antibodies Market Size and growth rate 2025 to 2029: Graph

Biosimilar Monoclonal Antibodies Market Size 2025 And Growth Rate

The biosimilar monoclonal antibodies market size has grown rapidly in recent years. It will grow from $8.04 billion in 2024 to $9.25 billion in 2025 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to patent expirations, growing awareness of biosimilars, government initiatives, increasing investment from pharmaceutical companies, and growing acceptance of biosimilars by clinicians and patients.

Biosimilar Monoclonal Antibodies Market Growth Forecast

The biosimilar monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $12.79 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to rising biologic expenditure, biosimilar portfolio expansion, personalization of biosimilar therapy, and increasing public interest in biosimilars. Major trends in the forecast period include therapeutic expansion, personalized biosimilars, collaborations and partnerships, biosimilar autoinjectors and devices, biobetters.

Biosimilar Monoclonal Antibodies Market Driver: Rising Prevalence Of Chronic Diseases Fuels Growth In The Biosimilar Monoclonal Antibodies Market

The prevalence of chronic diseases is expected to drive the biosimilar monoclonal antibodies market. Biosimilar monoclonal antibodies are used to treat chronic diseases such as cancer, autoimmune diseases, and rheumatoid arthritis. In cancer treatment, biosimilars of monoclonal antibodies such as trastuzumab, bevacizumab, and rituximab are used. Moreover, the incidence of cancer is increasing year by year. For instance, in February 2024, according to reports published by the Centers for Disease Control and Prevention (CDC), a US-based public health agency, a growing number of individuals in America are managing multiple chronic conditions, with 42% experiencing two or more, and 12% having five or more. Therefore, the prevalence of chronic diseases is expected to drive the growth of the biosimilar monoclonal antibodies market.

Biosimilar Monoclonal Antibodies Market Driver: Rising Geriatric Population Fuels Growth In The Biosimilar Monoclonal Antibodies Market

The rising geriatric population is expected to propel the growth of the biosimilar monoclonal antibodies market going forward. The geriatric population is the segment of the population that consists of older adults, typically defined as individuals who are 65 or older. Biosimilar monoclonal antibodies provide cost-effective access to essential therapies, improving treatment affordability and quality of life for older adults facing chronic diseases. For instance, in October 2022, according to the World Health Organization, a US-based specialized health agency, globally, 1 in 6 individuals would be 60 or older by 2030 and is expected to reach 2.1 billion elderly people by 2050. Therefore, the rising geriatric population is driving the growth of the biosimilar monoclonal antibodies market.

Global Biosimilar Monoclonal Antibodies Market Major Players

Major companies operating in the biosimilar monoclonal antibodies market include Pfizer Inc., Novartis AG, AbbVie Inc., Coherus BioSciences, Biocon Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., BioXpress Therapeutics SA, Intas Pharmaceuticals Limited, Genor BioPharma Co. Ltd., BIOCAD, Dr. Reddy's Laboratories Ltd., 3SBio Inc., Reliance Life Sciences, Hisun Pharmaceuticals, Celgen Biopharmaceuticals, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Shanghai Henlius Biotech Inc., Teva Pharmaceutical Industries Ltd., Alvotech, Xentria Inc., Lazuline Biotech Private Limited, Epygen Biotech Pvt Ltd., Mabpharm Limited, Qilu Pharmaceutical Co. Ltd., Chiatai Tianqing Pharmaceutical Group Co. Ltd., YL Biologics Ltd., Aprogen Biologics, UNDBIO Co Ltd., Samsung Bioepis Co. Ltd., ISU Abxis Corp., Bio-Rad Laboratories Inc.

Global Biosimilar Monoclonal Antibodies Market Trend: Advancements In Biosimilar Monoclonal Antibodies

Major companies operating in the biosimilar monoclonal antibodies market are focusing on developing cost-effective biosimilar therapies to gain a competitive advantage. These therapies are biologic medical products highly similar to already approved reference monoclonal antibodies, designed to provide affordable treatment options for various diseases, including cancer and autoimmune disorders. For instance, in 2022, Pfizer, a U.S.-based pharmaceutical company, launched Abrilada, a biosimilar to AbbVie's Humira (adalimumab). Abrilada features a comparable efficacy and safety profile to the original while offering significant cost savings for patients and healthcare systems. Additionally, it benefits from a streamlined approval process and robust manufacturing capabilities, enhancing patient access to essential treatments. This trend reflects a broader industry shift towards addressing rising healthcare costs while maintaining high-quality therapeutic options for patients

Global Biosimilar Monoclonal Antibodies Market Trend: Biocon Biologics and Janssen Biotech Enter Agreement to Enhance Access to Trastuzumab Biosimilar

Major companies in the biosimilar monoclonal antibody market are developing biosimilar versions of the monoclonal antibody to offer cost-effective alternatives to original monoclonal antibody therapies, improving access and affordability in healthcare. Intravenous formulation refers to a preparation of the antibody designed to be administered directly into the bloodstream through a vein for rapid therapeutic effect. For instance, in May 2024, Bio-Thera Solutions, a China-based biopharmaceutical company, and Biogen Inc., a US-based biopharmaceutical company launched TOFIDENCE (tocilizumab-bavi) in an intravenous formulation in the United States. The U.S. Food and Drug Administration approved TOFIDENCE in September 2023 for treating moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis. At launch, TOFIDENCE is available in three vial sizes—80 mg/4 mL, 200 mg/10 mL, and 400 mg/20 mL—for intravenous infusion, with subcutaneous formulations planned for future release.

Biosimilar Monoclonal Antibodies Market Merger And Acquisition: Biocon Biologics Ltd. Acquires Viatris Inc.'s Biosimilars Business To Strengthen Global Presence

In November 2022, Biocon Biologics Ltd., an India-based biopharmaceutical company, announced the acquisition of Viatris Inc. biosimilars business for an undisclosed sum. The acquisition brings Biocon Biologics closer to patients, customers, and payors by providing direct commercial capabilities and supporting infrastructure in advanced countries and numerous emerging regions. In numerous emerging market positions, the merger of Viatris acquired worldwide biosimilars company with Biocon Biologics' existing capabilities in research and development, global-scale manufacturing, and commercialization Viatris Inc. is a US-based pharmaceutical company that develops, licenses, manufactures, markets, and distributes generic and branded medicines.

Regional Outlook For The Global Biosimilar Monoclonal Antibodies Market

North America was the largest region in the biosimilar monoclonal antibodies market in 2024. The regions covered in the biosimilar monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the biosimilar monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

What Defines the Biosimilar Monoclonal Antibodies Market?

The biosimilar monoclonal antibodies market consists of sales of Blitzima, Ritemvia, Rituzena, and Truxima. Values in this market are ""factory gate values,"" that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Biosimilar Monoclonal Antibodies Industry?

The biosimilar monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides biosimilar monoclonal antibodies market statistics, including industry global market size, regional shares, competitors with a biosimilar monoclonal antibodies market share, detailed biosimilar monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar monoclonal antibodies industry. This biosimilar monoclonal antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Biosimilar Monoclonal Antibodies Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 $9.25 billion
Revenue Forecast In 2034 $12.79 billion
Growth Rate CAGR of 8.5% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Type: Synthetic Chemicals, Biopharmaceuticals, Other Types
2) By Compound: Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab
3) By Application: Chronic & Autoimmune Diseases, Oncology, Other Applications Subsegments: 1) By Synthetic Chemicals: Small Molecule Drugs, Chemical Synthesis Products
2) By Biopharmaceuticals: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Other Biopharmaceuticals
3) By Other Types: Antibody-Drug Conjugates, Fusion Proteins, Biosimilars Of Other Biologics
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., Novartis AG, AbbVie Inc., Coherus BioSciences, Biocon Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., BioXpress Therapeutics SA, Intas Pharmaceuticals Limited, Genor BioPharma Co. Ltd., BIOCAD, Dr. Reddy's Laboratories Ltd., 3SBio Inc., Reliance Life Sciences, Hisun Pharmaceuticals, Celgen Biopharmaceuticals, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Shanghai Henlius Biotech Inc., Teva Pharmaceutical Industries Ltd., Alvotech, Xentria Inc., Lazuline Biotech Private Limited, Epygen Biotech Pvt Ltd., Mabpharm Limited, Qilu Pharmaceutical Co. Ltd., Chiatai Tianqing Pharmaceutical Group Co. Ltd., YL Biologics Ltd., Aprogen Biologics, UNDBIO Co Ltd., Samsung Bioepis Co. Ltd., ISU Abxis Corp., Bio-Rad Laboratories Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Biosimilar Monoclonal Antibodies Market Characteristics

    3. Biosimilar Monoclonal Antibodies Market Trends And Strategies

    4. Biosimilar Monoclonal Antibodies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

    5. Global Biosimilar Monoclonal Antibodies Growth Analysis And Strategic Analysis Framework

    5.1. Global Biosimilar Monoclonal Antibodies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    5.2. Analysis Of End Use Industries

    5.3. Global Biosimilar Monoclonal Antibodies Market Growth Rate Analysis

    5.4. Global Biosimilar Monoclonal Antibodies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

    5.5. Global Biosimilar Monoclonal Antibodies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

    5.6. Global Biosimilar Monoclonal Antibodies Total Addressable Market (TAM)

    6. Biosimilar Monoclonal Antibodies Market Segmentation

    6.1. Global Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Synthetic Chemicals

    Biopharmaceuticals

    Other Types

    6.2. Global Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Infliximab

    Rituximab

    Abciximab

    Trastuzumab

    Adalimumab

    Bevacizumab

    6.3. Global Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Chronic & Autoimmune Diseases

    Oncology

    Other Applications

    6.4. Global Biosimilar Monoclonal Antibodies Market, Sub-Segmentation Of Synthetic Chemicals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Small Molecule Drugs

    Chemical Synthesis Products

    6.5. Global Biosimilar Monoclonal Antibodies Market, Sub-Segmentation Of Biopharmaceuticals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Monoclonal Antibodies

    Recombinant Proteins

    Vaccines

    Other Biopharmaceuticals

    6.6. Global Biosimilar Monoclonal Antibodies Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Antibody-Drug Conjugates

    Fusion Proteins

    Biosimilars Of Other Biologics

    7. Biosimilar Monoclonal Antibodies Market Regional And Country Analysis

    7.1. Global Biosimilar Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    7.2. Global Biosimilar Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8. Asia-Pacific Biosimilar Monoclonal Antibodies Market

    8.1. Asia-Pacific Biosimilar Monoclonal Antibodies Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.3. Asia-Pacific Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.4. Asia-Pacific Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    9. China Biosimilar Monoclonal Antibodies Market

    9.1. China Biosimilar Monoclonal Antibodies Market Overview

    9.2. China Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.3. China Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.4. China Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    10. India Biosimilar Monoclonal Antibodies Market

    10.1. India Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.2. India Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.3. India Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11. Japan Biosimilar Monoclonal Antibodies Market

    11.1. Japan Biosimilar Monoclonal Antibodies Market Overview

    11.2. Japan Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.3. Japan Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.4. Japan Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12. Australia Biosimilar Monoclonal Antibodies Market

    12.1. Australia Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.2. Australia Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.3. Australia Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13. Indonesia Biosimilar Monoclonal Antibodies Market

    13.1. Indonesia Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.2. Indonesia Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.3. Indonesia Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14. South Korea Biosimilar Monoclonal Antibodies Market

    14.1. South Korea Biosimilar Monoclonal Antibodies Market Overview

    14.2. South Korea Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.3. South Korea Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.4. South Korea Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15. Western Europe Biosimilar Monoclonal Antibodies Market

    15.1. Western Europe Biosimilar Monoclonal Antibodies Market Overview

    15.2. Western Europe Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.3. Western Europe Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.4. Western Europe Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16. UK Biosimilar Monoclonal Antibodies Market

    16.1. UK Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.2. UK Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.3. UK Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17. Germany Biosimilar Monoclonal Antibodies Market

    17.1. Germany Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.2. Germany Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.3. Germany Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18. France Biosimilar Monoclonal Antibodies Market

    18.1. France Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.2. France Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.3. France Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19. Italy Biosimilar Monoclonal Antibodies Market

    19.1. Italy Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.2. Italy Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.3. Italy Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20. Spain Biosimilar Monoclonal Antibodies Market

    20.1. Spain Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.2. Spain Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.3. Spain Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21. Eastern Europe Biosimilar Monoclonal Antibodies Market

    21.1. Eastern Europe Biosimilar Monoclonal Antibodies Market Overview

    21.2. Eastern Europe Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.3. Eastern Europe Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.4. Eastern Europe Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22. Russia Biosimilar Monoclonal Antibodies Market

    22.1. Russia Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.2. Russia Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.3. Russia Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23. North America Biosimilar Monoclonal Antibodies Market

    23.1. North America Biosimilar Monoclonal Antibodies Market Overview

    23.2. North America Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.3. North America Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.4. North America Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24. USA Biosimilar Monoclonal Antibodies Market

    24.1. USA Biosimilar Monoclonal Antibodies Market Overview

    24.2. USA Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.3. USA Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.4. USA Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25. Canada Biosimilar Monoclonal Antibodies Market

    25.1. Canada Biosimilar Monoclonal Antibodies Market Overview

    25.2. Canada Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.3. Canada Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.4. Canada Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26. South America Biosimilar Monoclonal Antibodies Market

    26.1. South America Biosimilar Monoclonal Antibodies Market Overview

    26.2. South America Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.3. South America Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.4. South America Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27. Brazil Biosimilar Monoclonal Antibodies Market

    27.1. Brazil Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.2. Brazil Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.3. Brazil Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28. Middle East Biosimilar Monoclonal Antibodies Market

    28.1. Middle East Biosimilar Monoclonal Antibodies Market Overview

    28.2. Middle East Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.3. Middle East Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.4. Middle East Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29. Africa Biosimilar Monoclonal Antibodies Market

    29.1. Africa Biosimilar Monoclonal Antibodies Market Overview

    29.2. Africa Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.3. Africa Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.4. Africa Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    30. Biosimilar Monoclonal Antibodies Market Competitive Landscape And Company Profiles

    30.1. Biosimilar Monoclonal Antibodies Market Competitive Landscape

    30.2. Biosimilar Monoclonal Antibodies Market Company Profiles

    30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

    30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.4. Coherus BioSciences Overview, Products and Services, Strategy and Financial Analysis

    30.2.5. Biocon Limited Overview, Products and Services, Strategy and Financial Analysis

    31. Biosimilar Monoclonal Antibodies Market Other Major And Innovative Companies

    31.1. Amgen Inc.

    31.2. Boehringer Ingelheim International GmbH

    31.3. Celltrion Inc.

    31.4. BioXpress Therapeutics SA

    31.5. Intas Pharmaceuticals Limited

    31.6. Genor BioPharma Co. Ltd.

    31.7. BIOCAD

    31.8. Dr. Reddy's Laboratories Ltd.

    31.9. 3SBio Inc.

    31.10. Reliance Life Sciences

    31.11. Hisun Pharmaceuticals

    31.12. Celgen Biopharmaceuticals

    31.13. Torrent Pharmaceuticals Ltd.

    31.14. Cadila Healthcare Ltd.

    31.15. Shanghai Henlius Biotech Inc.

    32. Global Biosimilar Monoclonal Antibodies Market Competitive Benchmarking And Dashboard

    33. Key Mergers And Acquisitions In The Biosimilar Monoclonal Antibodies Market

    34. Recent Developments In The Biosimilar Monoclonal Antibodies Market

    35. Biosimilar Monoclonal Antibodies Market High Potential Countries, Segments and Strategies

    35.1 Biosimilar Monoclonal Antibodies Market In 2029 - Countries Offering Most New Opportunities

    35.2 Biosimilar Monoclonal Antibodies Market In 2029 - Segments Offering Most New Opportunities

    35.3 Biosimilar Monoclonal Antibodies Market In 2029 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Biosimilar Monoclonal Antibodies Market, Sub-Segmentation Of Synthetic Chemicals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Biosimilar Monoclonal Antibodies Market, Sub-Segmentation Of Biopharmaceuticals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Biosimilar Monoclonal Antibodies Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Biosimilar Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Biosimilar Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Asia-Pacific, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: China, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: India, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: Japan, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Australia, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Indonesia, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: South Korea, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Western Europe, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: UK, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Germany, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: France, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Italy, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Spain, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Eastern Europe, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Russia, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: North America, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: USA, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: Canada, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: South America, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Brazil, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Middle East, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Africa, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Pfizer Inc. Financial Performance
  • Table 78: Novartis AG Financial Performance
  • Table 79: AbbVie Inc. Financial Performance
  • Table 80: Coherus BioSciences Financial Performance
  • Table 81: Biocon Limited Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Biosimilar Monoclonal Antibodies Market, Sub-Segmentation Of Synthetic Chemicals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Biosimilar Monoclonal Antibodies Market, Sub-Segmentation Of Biopharmaceuticals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Biosimilar Monoclonal Antibodies Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Biosimilar Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Biosimilar Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Asia-Pacific, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: China, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: India, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: Japan, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Australia, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Indonesia, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: South Korea, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Western Europe, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: UK, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Germany, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: France, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Italy, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Spain, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Eastern Europe, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Russia, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: North America, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: USA, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: Canada, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: South America, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Brazil, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Middle East, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Africa, Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Pfizer Inc. Financial Performance
  • Figure 78: Novartis AG Financial Performance
  • Figure 79: AbbVie Inc. Financial Performance
  • Figure 80: Coherus BioSciences Financial Performance
  • Figure 81: Biocon Limited Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the Biosimilar Monoclonal Antibodies market?

Biosimilar monoclonal antibodies refer to a member of the family of biosimilars. Large, intricate proteins are typically given as part of the treatment for conditions like cancer or rheumatoid arthritis. They are employed by the immune system to recognize and destroy foreign substances, including bacteria, viruses, and others. For further insights on the Biosimilar Monoclonal Antibodies market, request a sample here

How will the Biosimilar Monoclonal Antibodies market drivers and restraints affect the market dynamics? What forces will shape the Biosimilar Monoclonal Antibodies industry going forward?

The Biosimilar Monoclonal Antibodies market major growth driver - Rising Geriatric Population Fuels Growth In The Biosimilar Monoclonal Antibodies Market. For further insights on the Biosimilar Monoclonal Antibodies market, request a sample here

What is the forecast market size or the forecast market value of the Biosimilar Monoclonal Antibodies market?

The Biosimilar Monoclonal Antibodies market size has grown strongly in recent years. The biosimilar monoclonal antibodies market size has grown rapidly in recent years. It will grow from $8.04 billion in 2024 to $9.25 billion in 2025 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to patent expirations, growing awareness of biosimilars, government initiatives, increasing investment from pharmaceutical companies, and growing acceptance of biosimilars by clinicians and patients. The biosimilar monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $12.79 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to rising biologic expenditure, biosimilar portfolio expansion, personalization of biosimilar therapy, and increasing public interest in biosimilars. Major trends in the forecast period include therapeutic expansion, personalized biosimilars, collaborations and partnerships, biosimilar autoinjectors and devices, biobetters. For further insights on the Biosimilar Monoclonal Antibodies market, request a sample here

How is the Biosimilar Monoclonal Antibodies market segmented?

The biosimilar monoclonal antibodies market covered in this report is segmented –
1) By Type: Synthetic Chemicals, Biopharmaceuticals, Other Types
2) By Compound: Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab
3) By Application: Chronic & Autoimmune Diseases, Oncology, Other Applications
Subsegments:
1) By Synthetic Chemicals: Small Molecule Drugs, Chemical Synthesis Products
2) By Biopharmaceuticals: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Other Biopharmaceuticals
3) By Other Types: Antibody-Drug Conjugates, Fusion Proteins, Biosimilars Of Other Biologics For further insights on the Biosimilar Monoclonal Antibodies market,
request a sample here

Which region has the largest share of the Biosimilar Monoclonal Antibodies market? What are the other regions covered in the report?

North America was the largest region in the biosimilar monoclonal antibodies market in 2024. The regions covered in the biosimilar monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. For further insights on the Biosimilar Monoclonal Antibodies market, request a sample here.

Who are the major players in the Biosimilar Monoclonal Antibodies market?

Major companies operating in the biosimilar monoclonal antibodies market include Pfizer Inc., Novartis AG, AbbVie Inc., Coherus BioSciences, Biocon Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., BioXpress Therapeutics SA, Intas Pharmaceuticals Limited, Genor BioPharma Co. Ltd., BIOCAD, Dr. Reddy's Laboratories Ltd., 3SBio Inc., Reliance Life Sciences, Hisun Pharmaceuticals, Celgen Biopharmaceuticals, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Shanghai Henlius Biotech Inc., Teva Pharmaceutical Industries Ltd., Alvotech, Xentria Inc., Lazuline Biotech Private Limited, Epygen Biotech Pvt Ltd., Mabpharm Limited, Qilu Pharmaceutical Co. Ltd., Chiatai Tianqing Pharmaceutical Group Co. Ltd., YL Biologics Ltd., Aprogen Biologics, UNDBIO Co Ltd., Samsung Bioepis Co. Ltd., ISU Abxis Corp., Bio-Rad Laboratories Inc. . For further insights on the Biosimilar Monoclonal Antibodies market, request a sample here.

What are the key trends in the Biosimilar Monoclonal Antibodies market?

Major trends in the Biosimilar Monoclonal Antibodies market include Biocon Biologics and Janssen Biotech Enter Agreement to Enhance Access to Trastuzumab Biosimilar. For further insights on the Biosimilar Monoclonal Antibodies market, request a sample here.

What are the major opportunities in the Biosimilar Monoclonal Antibodies market? What are the strategies for the Biosimilar Monoclonal Antibodies market?

For detailed insights on the major opportunities and strategies in the Biosimilar Monoclonal Antibodies market, request a sample here.

How does the Biosimilar Monoclonal Antibodies market relate to the overall economy and other similar markets?

For detailed insights on Biosimilar Monoclonal Antibodies's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Biosimilar Monoclonal Antibodies industry?

For detailed insights on the mergers and acquisitions in the Biosimilar Monoclonal Antibodies industry, request a sample here.

What are the key dynamics influencing the Biosimilar Monoclonal Antibodies market growth? SWOT analysis of the Biosimilar Monoclonal Antibodies market.

For detailed insights on the key dynamics influencing the Biosimilar Monoclonal Antibodies market growth and SWOT analysis of the Biosimilar Monoclonal Antibodies industry, request a sample here.